SeekingAlpha · Aug 14, 2026
ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-14. The following slide deck was published by ImmuCell Corporation in conjunction with their 2026 Q2 earnings call.
IC
NASDAQ · ICCC
ImmuCell Corporation
Healthcare · Biotechnology
$9.71
Down-$0.14 (-1.42%)
Updated Sep 15, 2026, 2:58 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 54.28M
- P/E ratio
- 23.36
- Dividend yield
- 0.00%
- 52-week range
- $6.00 – $12.10
- Volume
- 14.82K
- Avg. volume
- 18.99K
Price performance
ICCC price history
1M range · 20 trading sessions · Daily adjusted prices
ICCC closed at $9.71 after 20 trading sessions, up 0.10% for the selected period.
- Last close
- $9.71
- Period change
- +0.10%
- Period low
- $9.70
- Period high
- $10.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | $9.80 | $9.85 | $9.71 | $9.71 | 14.82K |
| Sep 11, 2026 | $9.91 | $9.91 | $9.6341 | $9.85 | 8.1K |
| Sep 10, 2026 | $9.84 | $10.00 | $9.765 | $9.915 | 11.26K |
| Sep 9, 2026 | $9.81 | $9.95 | $9.79 | $9.91 | 8.5K |
| Sep 8, 2026 | $9.82 | $10.02 | $9.80 | $9.84 | 15.55K |
| Sep 4, 2026 | $9.97 | $9.97 | $9.80 | $9.90 | 11.7K |
| Sep 3, 2026 | $9.90 | $10.0399 | $9.90 | $10.00 | 14.27K |
| Sep 2, 2026 | $9.825 | $10.09 | $9.825 | $10.00 | 16.28K |
| Sep 1, 2026 | $9.85 | $10.015 | $9.835 | $9.92 | 6.99K |
| Aug 31, 2026 | $9.86 | $10.00 | $9.77 | $9.79 | 20.13K |
| Aug 28, 2026 | $10.298 | $10.298 | $9.89 | $9.94 | 5.61K |
| Aug 27, 2026 | $10.00 | $10.155 | $10.00 | $10.02 | 3.18K |
| Aug 26, 2026 | $9.85 | $10.3396 | $9.85 | $10.02 | 7.43K |
| Aug 25, 2026 | $9.87 | $10.12 | $9.73 | $9.84 | 27.47K |
| Aug 24, 2026 | $10.06 | $10.06 | $9.76 | $9.84 | 54.67K |
| Aug 21, 2026 | $10.09 | $10.4933 | $10.0501 | $10.06 | 11.13K |
| Aug 20, 2026 | $10.14 | $10.26 | $9.775 | $10.09 | 83.72K |
| Aug 19, 2026 | $9.76 | $10.375 | $9.61 | $10.13 | 48.76K |
| Aug 18, 2026 | $9.73 | $9.86 | $9.6291 | $9.76 | 15.15K |
| Aug 17, 2026 | $10.00 | $10.00 | $9.55 | $9.70 | 100.99K |
Latest ICCC news
The latest Smart Investors Daily articles mentioning ICCC.
Stock researchCompany · Overview
ICCC research
Overview
Company profile and research snapshot.
Company profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 14, 2026
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
Benzinga · Aug 14, 2026
ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript
ImmuCell (NASDAQ:ICCC) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Benzinga · Aug 13, 2026
ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.20 per share. This is a 233.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $7.186 million in sales
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
